Magnus Jakobsson
About Magnus Jakobsson
Magnus Jakobsson serves as the Director and Head of Proteomics at Acrivon Therapeutics, Inc., where he has worked since 2024. He has a strong background in proteomics, having held various academic and research positions, including roles at Lund University and the Novo Nordisk Foundation Center for Protein Research.
Current Role at Acrivon Therapeutics
Magnus Jakobsson serves as the Director and Head of Proteomics at Acrivon Therapeutics, Inc. since 2024. In this role, he utilizes advanced wet and dry lab proteomics infrastructure to support drug development and predictive diagnostics. He has been instrumental in the development of the Acrivon Predictive Precision Proteomics (AP3) platform, which focuses on the co-development of drugs and diagnostics.
Previous Experience at Novo Nordisk Foundation Center for Protein Research
Jakobsson worked at the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen as a Visiting Postdoc from 2016 to 2017. He continued his research there as a Postdoctoral Researcher from 2017 to 2019. His work during this period contributed to advancements in protein research and analysis.
Academic Background and Education
Magnus Jakobsson earned a Master's degree in Biotechnology from Lunds Technical Institute, where he studied from 2003 to 2009. His academic background laid the foundation for his expertise in proteomics and systems-level analysis.
Experience at Malmö University
Since 2022, Jakobsson has held the position of Adjunct Principal Investigator at Malmö University. In this role, he engages in research and collaboration, contributing to the academic community and advancing knowledge in proteomics.
Roles at Lund University
Jakobsson has held multiple positions at Lund University, including Senior Lecturer from 2021 to 2022 and Associate Senior Lecturer in Proteomics from 2019 to 2021. He also served as an Associate Professor from 2021 to 2022, where he focused on teaching and research in the field of proteomics.